MedTrace Logo

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

NCT04527250 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-08-20

No results posted yet for this study

Summary

The objective of this study is to compare the pharmacokinetic parameters of ASC41 in healthy subjects after single and multiple oral dosing.

Conditions

  • Healthy

Interventions

DRUG

ASC41

ASC41,1mg/table;5mg/table

DRUG

ASC41 placebo

ASC41 placebo,1mg/table;5mg/table

Sponsors & Collaborators

  • Hunan Provincial People's Hospital

    collaborator OTHER

  • Ascletis Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-09-16
Primary Completion
2020-12-18
Completion
2020-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527250 on ClinicalTrials.gov